Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.

Prime ME, Andersen OA, Barker JJ, Brooks MA, Cheng RK, Toogood-Johnson I, Courtney SM, Brookfield FA, Yarnold CJ, Marston RW, Johnson PD, Johnsen SF, Palfrey JJ, Vaidya D, Erfan S, Ichihara O, Felicetti B, Palan S, Pedret-Dunn A, Schaertl S, Sternberger I, Ebneth A, Scheel A, Winkler D, Toledo-Sherman L, Beconi M, Macdonald D, Muñoz-Sanjuan I, Dominguez C, Wityak J.

J Med Chem. 2012 Feb 9;55(3):1021-46. doi: 10.1021/jm201310y. Epub 2012 Jan 27.

PMID:
22224594
2.

A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors.

Schaertl S, Prime M, Wityak J, Dominguez C, Munoz-Sanjuan I, Pacifici RE, Courtney S, Scheel A, Macdonald D.

J Biomol Screen. 2010 Jun;15(5):478-87. doi: 10.1177/1087057110366035. Epub 2010 Apr 15.

PMID:
20395409
3.

'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease.

Mastroberardino PG, Iannicola C, Nardacci R, Bernassola F, De Laurenzi V, Melino G, Moreno S, Pavone F, Oliverio S, Fesus L, Piacentini M.

Cell Death Differ. 2002 Sep;9(9):873-80.

4.

Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.

Kumar A, Kneynsberg A, Tucholski J, Perry G, van Groen T, Detloff PJ, Lesort M.

Exp Neurol. 2012 Sep;237(1):78-89. doi: 10.1016/j.expneurol.2012.05.015. Epub 2012 Jun 12.

5.

Cinnamoyl inhibitors of tissue transglutaminase.

Pardin C, Pelletier JN, Lubell WD, Keillor JW.

J Org Chem. 2008 Aug 1;73(15):5766-75. doi: 10.1021/jo8004843. Epub 2008 Jun 27.

PMID:
18582115
6.

Molecular characterization of covalent complexes between tissue transglutaminase and gliadin peptides.

Fleckenstein B, Qiao SW, Larsen MR, Jung G, Roepstorff P, Sollid LM.

J Biol Chem. 2004 Apr 23;279(17):17607-16. Epub 2004 Jan 27.

7.

Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.

Grosso H, Mouradian MM.

Pharmacol Ther. 2012 Mar;133(3):392-410. doi: 10.1016/j.pharmthera.2011.12.003. Epub 2011 Dec 22. Review.

PMID:
22212614
8.

Recent advances in the development of tissue transglutaminase (TG2) inhibitors.

Badarau E, Collighan RJ, Griffin M.

Amino Acids. 2013 Jan;44(1):119-27. doi: 10.1007/s00726-011-1188-4. Epub 2011 Dec 13. Review.

PMID:
22160259
9.

Therapeutic effects of cystamine in a murine model of Huntington's disease.

Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ.

J Neurosci. 2002 Oct 15;22(20):8942-50.

10.

Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.

Smith AL, D'Angelo ND, Bo YY, Booker SK, Cee VJ, Herberich B, Hong FT, Jackson CL, Lanman BA, Liu L, Nishimura N, Pettus LH, Reed AB, Tadesse S, Tamayo NA, Wurz RP, Yang K, Andrews KL, Whittington DA, McCarter JD, Miguel TS, Zalameda L, Jiang J, Subramanian R, Mullady EL, Caenepeel S, Freeman DJ, Wang L, Zhang N, Wu T, Hughes PE, Norman MH.

J Med Chem. 2012 Jun 14;55(11):5188-219. doi: 10.1021/jm300184s. Epub 2012 May 23.

PMID:
22548365
13.

Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

Dai Y, Dudek NL, Li Q, Fowler SC, Muma NA.

J Neurosci. 2009 Sep 16;29(37):11550-9. doi: 10.1523/JNEUROSCI.3307-09.2009.

14.

Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.

Pardin C, Roy I, Chica RA, Bonneil E, Thibault P, Lubell WD, Pelletier JN, Keillor JW.

Biochemistry. 2009 Apr 21;48(15):3346-53. doi: 10.1021/bi802021c.

PMID:
19271761
15.

Déjà vu with a twist: transglutaminases in bioenergetics and transcriptional dysfunction in Huntington's disease.

Kazemi-Esfarjani P, La Spada AR.

EMBO Mol Med. 2010 Sep;2(9):335-7. doi: 10.1002/emmm.201000092.

16.

Recent advances in understanding the roles of transglutaminase 2 in alcoholic steatohepatitis.

Tatsukawa H, Kojima S.

Cell Biol Int. 2010 Feb 22;34(3):325-34. doi: 10.1042/CBI20090130. Review.

PMID:
20192918
17.

Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential.

Mastroberardino PG, Piacentini M.

J Intern Med. 2010 Nov;268(5):419-31. doi: 10.1111/j.1365-2796.2010.02275.x. Review.

18.

Mutation of a critical arginine in the GTP-binding site of transglutaminase 2 disinhibits intracellular cross-linking activity.

Begg GE, Holman SR, Stokes PH, Matthews JM, Graham RM, Iismaa SE.

J Biol Chem. 2006 May 5;281(18):12603-9. Epub 2006 Mar 7.

19.

Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.

Choi K, Siegel M, Piper JL, Yuan L, Cho E, Strnad P, Omary B, Rich KM, Khosla C.

Chem Biol. 2005 Apr;12(4):469-75.

20.

Supplemental Content

Support Center